JP2007523863A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007523863A5 JP2007523863A5 JP2006517407A JP2006517407A JP2007523863A5 JP 2007523863 A5 JP2007523863 A5 JP 2007523863A5 JP 2006517407 A JP2006517407 A JP 2006517407A JP 2006517407 A JP2006517407 A JP 2006517407A JP 2007523863 A5 JP2007523863 A5 JP 2007523863A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antigen
- set according
- epitope
- immunopotentiator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 71
- 239000000427 antigen Substances 0.000 claims 47
- 102000036639 antigens Human genes 0.000 claims 47
- 108091007433 antigens Proteins 0.000 claims 47
- 230000002163 immunogen Effects 0.000 claims 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims 27
- 230000028993 immune response Effects 0.000 claims 21
- 230000000091 immunopotentiator Effects 0.000 claims 20
- 230000003321 amplification Effects 0.000 claims 19
- 238000003199 nucleic acid amplification method Methods 0.000 claims 19
- 210000004324 lymphatic system Anatomy 0.000 claims 12
- 241000124008 Mammalia Species 0.000 claims 11
- 230000001939 inductive effect Effects 0.000 claims 10
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 10
- 150000007523 nucleic acids Chemical class 0.000 claims 10
- 230000003053 immunization Effects 0.000 claims 9
- 102000004127 Cytokines Human genes 0.000 claims 7
- 108090000695 Cytokines Proteins 0.000 claims 7
- 230000005867 T cell response Effects 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 241000700605 Viruses Species 0.000 claims 6
- 210000003162 effector t lymphocyte Anatomy 0.000 claims 6
- 210000001165 lymph node Anatomy 0.000 claims 5
- 244000052769 pathogen Species 0.000 claims 5
- 230000001717 pathogenic effect Effects 0.000 claims 5
- 241000894006 Bacteria Species 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000004044 response Effects 0.000 claims 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 3
- 101100462972 Mus musculus Pcdh8 gene Proteins 0.000 claims 3
- 238000002649 immunization Methods 0.000 claims 3
- 230000003308 immunostimulating effect Effects 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 230000003614 tolerogenic effect Effects 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 102000019034 Chemokines Human genes 0.000 claims 2
- 108010012236 Chemokines Proteins 0.000 claims 2
- 102000002689 Toll-like receptor Human genes 0.000 claims 2
- 108020000411 Toll-like receptor Proteins 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 230000003190 augmentative effect Effects 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 210000002421 cell wall Anatomy 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 230000000977 initiatory effect Effects 0.000 claims 2
- 102000007863 pattern recognition receptors Human genes 0.000 claims 2
- 108010089193 pattern recognition receptors Proteins 0.000 claims 2
- 230000000770 proinflammatory effect Effects 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- PIGTXFOGKFOFTO-FVFWYJKVSA-N (2S,3S,4S,5R,6R)-6-[[(3S,4S,4aR,6aR,6bS,8R,8aR,12aS,14aR,14bR)-8a-carboxy-4-formyl-8-hydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)C[C@@H](O)[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O PIGTXFOGKFOFTO-FVFWYJKVSA-N 0.000 claims 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- XEDONBRPTABQFB-UHFFFAOYSA-N 4-[(2-formyl-3-hydroxyphenoxy)methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1COC1=CC=CC(O)=C1C=O XEDONBRPTABQFB-UHFFFAOYSA-N 0.000 claims 1
- 108700012434 CCL3 Proteins 0.000 claims 1
- 102000000013 Chemokine CCL3 Human genes 0.000 claims 1
- 102000001327 Chemokine CCL5 Human genes 0.000 claims 1
- 108010055166 Chemokine CCL5 Proteins 0.000 claims 1
- 238000011510 Elispot assay Methods 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims 1
- 102000003814 Interleukin-10 Human genes 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 102000000743 Interleukin-5 Human genes 0.000 claims 1
- 206010061309 Neoplasm progression Diseases 0.000 claims 1
- 102000029797 Prion Human genes 0.000 claims 1
- 108091000054 Prion Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 238000002784 cytotoxicity assay Methods 0.000 claims 1
- 231100000263 cytotoxicity test Toxicity 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 210000001365 lymphatic vessel Anatomy 0.000 claims 1
- 239000006166 lysate Substances 0.000 claims 1
- 229920002521 macromolecule Polymers 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 210000005170 neoplastic cell Anatomy 0.000 claims 1
- 210000002741 palatine tonsil Anatomy 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229950009795 tucaresol Drugs 0.000 claims 1
- 230000005751 tumor progression Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47939303P | 2003-06-17 | 2003-06-17 | |
| US60/479,393 | 2003-06-17 | ||
| PCT/US2004/019546 WO2005002621A2 (en) | 2003-06-17 | 2004-06-17 | Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012198859A Division JP2013028619A (ja) | 2003-06-17 | 2012-09-10 | 予防又は治療目的のためのｍｈｃクラスｉ拘束性エピトープに対する免疫応答を誘発し、増強し、維持する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007523863A JP2007523863A (ja) | 2007-08-23 |
| JP2007523863A5 true JP2007523863A5 (https=) | 2010-06-17 |
| JP5127224B2 JP5127224B2 (ja) | 2013-01-23 |
Family
ID=33563795
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006517407A Expired - Fee Related JP5127224B2 (ja) | 2003-06-17 | 2004-06-17 | 予防又は治療目的のためのｍｈｃクラスｉ拘束性エピトープに対する免疫応答を誘発し、増強し、維持する方法 |
| JP2012198859A Pending JP2013028619A (ja) | 2003-06-17 | 2012-09-10 | 予防又は治療目的のためのｍｈｃクラスｉ拘束性エピトープに対する免疫応答を誘発し、増強し、維持する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012198859A Pending JP2013028619A (ja) | 2003-06-17 | 2012-09-10 | 予防又は治療目的のためのｍｈｃクラスｉ拘束性エピトープに対する免疫応答を誘発し、増強し、維持する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20050079152A1 (https=) |
| EP (3) | EP2356999A1 (https=) |
| JP (2) | JP5127224B2 (https=) |
| AT (1) | ATE476196T1 (https=) |
| AU (1) | AU2004253479B9 (https=) |
| CA (1) | CA2529057A1 (https=) |
| DE (1) | DE602004028468D1 (https=) |
| DK (1) | DK1635863T3 (https=) |
| ES (1) | ES2350043T3 (https=) |
| MX (1) | MXPA05013973A (https=) |
| PL (1) | PL1635863T3 (https=) |
| WO (1) | WO2005002621A2 (https=) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6727230B1 (en) * | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
| US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6977074B2 (en) * | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
| US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
| US6693086B1 (en) * | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| ES2572834T3 (es) | 1999-02-17 | 2016-06-02 | Csl Limited | Complejos inmunogénicos y métodos relacionados con los mismos |
| NZ520976A (en) * | 1999-11-19 | 2005-01-28 | Csl Ltd | Vaccine compositions |
| US20040131628A1 (en) * | 2000-03-08 | 2004-07-08 | Bratzler Robert L. | Nucleic acids for the treatment of disorders associated with microorganisms |
| KR100917101B1 (ko) * | 2000-08-04 | 2009-09-15 | 도요 보세키 가부시키가이샤 | 플렉시블 금속적층체 및 그 제조방법 |
| US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7576066B2 (en) * | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7605138B2 (en) * | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US20040053880A1 (en) * | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7569553B2 (en) * | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| CN1753687A (zh) * | 2002-10-29 | 2006-03-29 | 科勒制药集团股份有限公司 | Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用 |
| AU2004226605A1 (en) * | 2003-04-02 | 2004-10-14 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations for topical application |
| US7178491B2 (en) * | 2003-06-05 | 2007-02-20 | Caterpillar Inc | Control system and method for engine valve actuator |
| US20060008468A1 (en) * | 2004-06-17 | 2006-01-12 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
| US20060159689A1 (en) * | 2004-06-17 | 2006-07-20 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
| CA2571168A1 (en) * | 2004-06-17 | 2006-01-26 | Mannkind Corporation | Mhc i-binding ssx-241-49 variants |
| US20050287068A1 (en) * | 2004-06-17 | 2005-12-29 | Bot Adrian I | Efficacy of active immunotherapy by integrating diagnostic with therapeutic methods |
| WO2007001448A2 (en) | 2004-11-04 | 2007-01-04 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
| EP1838338A2 (en) * | 2004-12-29 | 2007-10-03 | Mannkind Corporation | Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs |
| PL1833506T3 (pl) * | 2004-12-29 | 2016-01-29 | Mannkind Corp | Zastosowanie kompozycji zawierających różne antygeny związane z nowotworem jako szczepionek przeciwnowotworowych |
| JP2008526763A (ja) * | 2004-12-29 | 2008-07-24 | マンカインド コーポレイション | 予防又は治療目的のｍｈｃクラスｉ拘束性エピトープに対する免疫応答の誘導、増強及び保持方法 |
| CA2592972A1 (en) * | 2004-12-29 | 2006-07-06 | Mannkind Corporation | Methods to bypass cd+4 cells in the induction of an immune response |
| NZ564359A (en) * | 2005-06-17 | 2011-09-30 | Mannkind Corp | Analogs of pepetides corresponding to class I MHC-restricted T cell epitopes |
| SG162817A1 (en) * | 2005-06-17 | 2010-07-29 | Mannkind Corp | Methods and compositions.to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma |
| AU2006259221B8 (en) * | 2005-06-17 | 2013-02-07 | Mannkind Corporation | Multivalent entrain-and-amplify immunotherapeutics for carcinoma |
| KR20080030656A (ko) * | 2005-07-07 | 2008-04-04 | 콜레이 파마시티컬 그룹, 인코포레이티드 | 암 치료를 위한 항-ＣＴＬＡ-4 항체 및 ＣｐＧ-모티프-함유합성 올리고데옥시뉴클레오티드의 조합 요법 |
| EP1792627A1 (en) * | 2005-12-05 | 2007-06-06 | ImVisioN AG | Modulation of the immune response by administration of intralymphatic transduction allergen (ITAG-)-molecules |
| WO2007065633A1 (en) * | 2005-12-05 | 2007-06-14 | Imvision Ag | Modulation of the immune response by administration of intralymphatic transduction allergen (itag) -molecules |
| WO2007070682A2 (en) | 2005-12-15 | 2007-06-21 | Massachusetts Institute Of Technology | System for screening particles |
| US20090061478A1 (en) * | 2006-01-30 | 2009-03-05 | Lene Have Poulsen | High-Speed Quantification of Antigen Specific T-Cells in Whole Blood by Flow Cytometry |
| CA2648099C (en) * | 2006-03-31 | 2012-05-29 | The Brigham And Women's Hospital, Inc | System for targeted delivery of therapeutic agents |
| JP5630998B2 (ja) | 2006-05-15 | 2014-11-26 | マサチューセッツ インスティテュート オブ テクノロジー | 機能的粒子のためのポリマー |
| WO2007144772A2 (en) * | 2006-06-15 | 2007-12-21 | Novartis Ag | Adjuvant-sparing multi-dose influenza vaccination regimen |
| WO2007150030A2 (en) * | 2006-06-23 | 2007-12-27 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
| JP2009544610A (ja) * | 2006-07-14 | 2009-12-17 | マンカインド コーポレイション | 予防又は治療目的のためにｍｈｃクラスｉ拘束エピトープに対する免疫応答を引き出し、増強し、保持する方法 |
| WO2008019142A2 (en) * | 2006-08-04 | 2008-02-14 | Massachusetts Institute Of Technology | Oligonucleotide systems for targeted intracellular delivery |
| EP2134830A2 (en) | 2007-02-09 | 2009-12-23 | Massachusetts Institute of Technology | Oscillating cell culture bioreactor |
| CN103736086A (zh) * | 2007-02-15 | 2014-04-23 | 曼康公司 | 用于增强t细胞应答的方法 |
| WO2008116468A2 (en) | 2007-03-26 | 2008-10-02 | Dako Denmark A/S | Mhc peptide complexes and uses thereof in infectious diseases |
| CN101687022B (zh) * | 2007-03-26 | 2016-09-07 | 莱顿大学医学中心附属莱顿教学医院 | Prame衍生的肽以及包括该肽的免疫原组合物 |
| JP2010523595A (ja) * | 2007-04-04 | 2010-07-15 | マサチューセッツ インスティテュート オブ テクノロジー | ポリ（アミノ酸）ターゲッティング部分 |
| EP3620465B1 (en) | 2007-07-03 | 2025-02-19 | Dako Denmark A/S | Improved methods for generation, labeling and use of mhc multimers |
| US10611818B2 (en) | 2007-09-27 | 2020-04-07 | Agilent Technologies, Inc. | MHC multimers in tuberculosis diagnostics, vaccine and therapeutics |
| JP2011500569A (ja) | 2007-10-12 | 2011-01-06 | マサチューセッツ インスティテュート オブ テクノロジー | ワクチンナノテクノロジー |
| DK2254592T3 (da) | 2008-02-28 | 2019-09-09 | Dako Denmark As | MHC-multimerer til Borrelia-diagnostik og sygdom |
| WO2010009735A2 (en) | 2008-07-23 | 2010-01-28 | Dako Denmark A/S | Combinatorial analysis and repair |
| GB0817244D0 (en) | 2008-09-20 | 2008-10-29 | Univ Cardiff | Use of a protein kinase inhibitor to detect immune cells, such as T cells |
| US11992518B2 (en) | 2008-10-02 | 2024-05-28 | Agilent Technologies, Inc. | Molecular vaccines for infectious disease |
| WO2010037402A1 (en) | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
| US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
| US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
| US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
| AU2010310468A1 (en) | 2009-10-23 | 2012-05-24 | Mannkind Corporation | Cancer immunotherapy and method of treatment |
| EA201390660A1 (ru) | 2010-11-05 | 2013-11-29 | Селекта Байосайенсиз, Инк. | Модифицированные никотиновые соединения и связанные способы |
| WO2020127222A2 (en) | 2018-12-17 | 2020-06-25 | Immudex Aps | Panel comprising borrelia mhc multimers |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2606601A (en) | 1948-12-14 | 1952-08-12 | Knoll Associates | Chair having a back rest in the form of a shell-like body |
| AU7983198A (en) * | 1997-06-23 | 1999-01-04 | Ludwig Institute For Cancer Research | Improved methods for inducing an immune response |
| ES2265165T3 (es) * | 1997-07-10 | 2007-02-01 | Mannkind Corporation | Dispositivo para inducir una respuesta ltc. |
| US6977074B2 (en) * | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
| US6709844B1 (en) | 2000-11-16 | 2004-03-23 | Mannkind Corporation | Avoidance of undesirable replication intermediates in plasmid propagation |
| US20030138808A1 (en) | 1998-02-19 | 2003-07-24 | Simard John J.L. | Expression vectors encoding epitopes of target-associated antigens |
| CA2388337C (en) * | 1999-10-22 | 2013-01-08 | Aventis Pasteur Limited | Method of inducing and/or enhancing an immune response to tumor antigens |
| US20030215425A1 (en) | 2001-12-07 | 2003-11-20 | Simard John J. L. | Epitope synchronization in antigen presenting cells |
| US6861234B1 (en) * | 2000-04-28 | 2005-03-01 | Mannkind Corporation | Method of epitope discovery |
| US6773695B2 (en) * | 2000-10-05 | 2004-08-10 | Mannkind Corporation | Modulation of allergic response |
| US7252824B2 (en) * | 2001-03-07 | 2007-08-07 | Mannkind Corporation | Anti-neovasculature preparations for cancer |
| CA2439111A1 (en) * | 2001-04-05 | 2002-10-17 | Chiron Corporation | Mucosal boosting following parenteral priming |
| WO2003008537A2 (en) | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
| US7076244B2 (en) | 2001-07-23 | 2006-07-11 | Research In Motion Limited | System and method for pushing information to a mobile device |
| GB0118532D0 (en) * | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
| CN101024842A (zh) | 2001-11-07 | 2007-08-29 | 曼康公司 | 编码靶相关抗原表位的表达载体及其设计方法 |
| CA2467486A1 (en) * | 2001-11-30 | 2003-06-12 | Isis Innovation Limited | Vaccine |
| AU2003270311A1 (en) | 2002-09-06 | 2004-03-29 | Mannkind Corporation | Epitope sequences |
| US20060257416A1 (en) * | 2003-06-13 | 2006-11-16 | Palmowski J M | Materials and methods for improved vaccination |
| US9469902B2 (en) | 2014-02-18 | 2016-10-18 | Lam Research Corporation | Electroless deposition of continuous platinum layer |
| US9814289B2 (en) | 2015-04-08 | 2017-11-14 | Otter Products, Llc | Protective folio case for an electronic device |
| EP3636238B1 (en) | 2018-10-12 | 2021-04-28 | Liko Research & Development AB | Gates with transition ramps for overhead lifting rails |
-
2004
- 2004-06-17 DK DK04776760.3T patent/DK1635863T3/da active
- 2004-06-17 EP EP10180566A patent/EP2356999A1/en not_active Ceased
- 2004-06-17 EP EP04776760A patent/EP1635863B1/en not_active Expired - Lifetime
- 2004-06-17 CA CA002529057A patent/CA2529057A1/en not_active Abandoned
- 2004-06-17 EP EP10171754.4A patent/EP2246067B1/en not_active Expired - Lifetime
- 2004-06-17 PL PL04776760T patent/PL1635863T3/pl unknown
- 2004-06-17 ES ES04776760T patent/ES2350043T3/es not_active Expired - Lifetime
- 2004-06-17 JP JP2006517407A patent/JP5127224B2/ja not_active Expired - Fee Related
- 2004-06-17 AU AU2004253479A patent/AU2004253479B9/en not_active Ceased
- 2004-06-17 MX MXPA05013973A patent/MXPA05013973A/es active IP Right Grant
- 2004-06-17 US US10/871,707 patent/US20050079152A1/en not_active Abandoned
- 2004-06-17 WO PCT/US2004/019546 patent/WO2005002621A2/en not_active Ceased
- 2004-06-17 DE DE602004028468T patent/DE602004028468D1/de not_active Expired - Lifetime
- 2004-06-17 AT AT04776760T patent/ATE476196T1/de active
-
2012
- 2012-09-10 JP JP2012198859A patent/JP2013028619A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007523863A5 (https=) | ||
| Kayraklioglu et al. | CpG oligonucleotides as vaccine adjuvants | |
| Cui et al. | Flagellin as a vaccine adjuvant | |
| Bode et al. | CpG DNA as a vaccine adjuvant | |
| Klinman | Immunotherapeutic uses of CpG oligodeoxynucleotides | |
| Klinman et al. | Use of CpG oligodeoxynucleotides as immune adjuvants | |
| Lin et al. | Vaccine-induced antigen-specific regulatory T cells attenuate the antiviral immunity against acute influenza virus infection | |
| Ellis | New technologies for making vaccines | |
| Salonius et al. | The road to licensure of a DNA vaccine | |
| Cui | DNA vaccine | |
| Zepp | Principles of vaccine design—lessons from nature | |
| Leroux-Roels | Unmet needs in modern vaccinology: adjuvants to improve the immune response | |
| JP2010519205A5 (https=) | ||
| Higgins et al. | Immunostimulatory DNA as a vaccine adjuvant | |
| JP5709264B2 (ja) | ワクチン組成物および方法 | |
| Wang et al. | Immunizations with hepatitis B viral antigens and a TLR7/8 agonist adjuvant induce antigen-specific immune responses in HBV-transgenic mice | |
| Pham et al. | Exploiting cross-priming to generate protective CD8 T-cell immunity rapidly | |
| Hudu et al. | An overview of recombinant vaccine technology, adjuvants and vaccine delivery methods | |
| Farhud et al. | A brief overview of COVID-19 vaccines | |
| Stephen et al. | Swine influenza virus vaccine: potentiation of antibody responses in rhesus monkeys | |
| Wang et al. | Innate endogenous adjuvants prime to desirable immune responses via mucosal routes | |
| JP2006502228A5 (https=) | ||
| US20240350619A1 (en) | Vaccines and compositions based on sars-cov-2 s protein | |
| Webster | Potential advantages of DNA immunization for influenza epidemic and pandemic planning | |
| Chen et al. | Plasmids enriched with CpG motifs activate human peripheral blood mononuclear cells in vitro and enhance th-1 immune responses to hepatitis B surface antigen in mice |